Experimental Hematology & Oncology

Papers
(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
Complex roles of cAMP–PKA–CREB signaling in cancer244
CD44 as a tumor biomarker and therapeutic target206
Role of m6A writers, erasers and readers in cancer100
Research progress on dendritic cell vaccines in cancer immunotherapy82
Heterogeneity of the tumor immune microenvironment and its clinical relevance73
Breast cancer heterogeneity and its implication in personalized precision therapy73
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies72
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–201769
Engineering better chimeric antigen receptor T cells68
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC67
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment62
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition61
MiRNA-mediated EMT and CSCs in cancer chemoresistance54
Recent advances and challenges of bispecific antibodies in solid tumors52
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL51
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia44
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder43
Current insight into the regulation of PD-L1 in cancer41
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma41
m6A binding protein YTHDF2 in cancer41
Increasing cure rates of solid tumors by immune checkpoint inhibitors40
TRIM family contribute to tumorigenesis, cancer development, and drug resistance39
Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development39
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma39
COVID-19 vaccination associated severe immune thrombocytopenia38
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients37
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors36
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A436
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment35
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy35
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy34
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma33
TCR engineered T cells for solid tumor immunotherapy33
Recent advances in Lynch syndrome32
Roles of the intestinal microbiota and microbial metabolites in acute GVHD32
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors31
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside27
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas26
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis25
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin25
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma24
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation24
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome24
New insight into circRNAs: characterization, strategies, and biomedical applications23
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas23
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential23
Ferroptosis: a novel regulated cell death participating in cellular stress response, radiotherapy, and immunotherapy23
p53 amyloid aggregation in cancer: function, mechanism, and therapy22
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy22
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study22
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia22
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma22
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy22
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer21
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance21
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review21
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing21
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio21
RHO GTPase family in hepatocellular carcinoma21
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy20
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes20
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis19
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis19
Current approaches to develop “off-the-shelf” chimeric antigen receptor (CAR)-T cells for cancer treatment: a systematic review19
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation19
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers18
Focal adhesion kinase: from biological functions to therapeutic strategies18
Targeting metabolic reprogramming in chronic lymphocytic leukemia18
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner18
Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce18
Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD18
CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model17
New insights into epigenetic regulation of resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms and therapeutic opportunities17
The metabolic adaptation mechanism of metastatic organotropism17
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel17
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma17
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion16
Function and clinical significance of N6-methyladenosine in digestive system tumours16
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer16
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation16
Chimeric antigen receptor engineered natural killer cells for cancer therapy16
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia16
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information16
Recent updates for antibody therapy for acute lymphoblastic leukemia15
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma15
The role of organoids in cancer research15
CD44 promotes hepatocellular carcinoma progression via upregulation of YAP15
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases15
Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia14
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target14
Increased TOX expression associates with exhausted T cells in patients with multiple myeloma14
COVID-19-associated coagulopathy: thromboembolism prophylaxis and poor prognosis in ICU14
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment14
Targeting phosphoglycerate dehydrogenase in multiple myeloma14
CDCA8 induced by NF-YA promotes hepatocellular carcinoma progression by regulating the MEK/ERK pathway13
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway13
0.046983003616333